scholarly journals Evaluation of Variations in the Various Blood Indices in COVID-19 Recovered Patients

2021 ◽  
pp. 577-586
Author(s):  
T. Srinivasa Surya Sitaram ◽  
Palati Sinduja ◽  
R. Priyadharshini ◽  
V. Meghashree
Keyword(s):  
Blood Parameters ◽  
World Health ◽  
Total Blood ◽  
Blood Samples ◽  
Blood Indices ◽  
Error Bar ◽  
Wbc Count ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Rbc Count

Introduction: In December 2019, cases of pneumonia with an unknown cause were reported in Wuhan, Hubei Province, China. Novel coronavirus infectious disease (COVID-19) has been spreading worldwide and tracking laboratory indexes during the diagnosis and treatment of patients with severe COVID-19 can provide a reference for patients in other countries and regions. The disease is caused by the Severe Acute Respiratory Syndrome Coronavirus according to studies, and the World Health Organization just dubbed it coronavirus disease 2019. Aim: The aim of this analysis was to evaluate COVID-19 patients' blood parameters changes in comparison with healthy controlled patients. Methods: Blood samples were taken from 10 patients in which 5 are COVID-19 recovered patients and 5 are healthy controls. For these blood samples TBC (Total Blood Count) was taken and the readings of RBC, hemoglobin, WBC, lymphocyte, granulocyte and platelets count was recorded. Independent t-test was done to obtain the results. SPSS software Version 23 was used to give the output comparison as error bar charts. Results: The patients have increased RBC count, increased hemoglobin and reduced WBC count with reduced lymphocytes and Granulocytes counts. Here it can be concluded that COVID-19 recovered patients should take care of themselves by having proper care, doctor consultation and follow up. Conclusion: From this study it can be understood that COVID-19 recovered patients have increased RBC count and hemoglobin percentage. The recovered patients have reduced WBC, lymphocytes and Granulocytes percentage.

scholarly journals Co-infection of COVID-19 and Influenza A in A Hemodialysis Patient: A Case Report

2020 ◽  
Author(s):  
Ran Jing ◽  
Rama R Vunnam ◽  
Elizabeth Schnaubelt ◽  
Chad Vokoun ◽  
Allison Cushman-Vokoun ◽  
...  
Keyword(s):  
Influenza A ◽  
Clinical Symptoms ◽  
Influenza Viruses ◽  
World Health ◽  
Nasopharyngeal Swab ◽  
Healthcare Facilities ◽  
Normal White Blood Cell ◽  
Wbc Count ◽  
Novel Coronavirus ◽  
Health Organization

Abstract Background: Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel coronavirus that was first discovered in Wuhan, China in December 2019. With the growing numbers of community spread cases worldwide, the World Health Organization (WHO) declared the COVID-19 outbreak as a pandemic on March 11. Like influenza viruses, SARS-CoV-2 is thought to be transmitted by contact, droplets, and fomites, and COVID-19 has a similar disease presentation to influenza. Here we present a case of influenza A and COVID-19 co-infection in a 60-year-old man with end-stage renal disease (ESRD) on hemodialysis.Case presentation: A 60-year-old man with ESRD on hemodialysis (HD) presented for worsening cough, shortness of breath, and diarrhea. The patient first developed a mild fever (100 °F) during hemodialysis three days prior to presentation and has been experiencing worsening flu-like symptoms, including fever of up to 101.6 °F, non-productive cough, generalized abdominal pain, nausea, vomiting, and liquid green diarrhea. He lives alone at home with no known sick contacts and denies any recent travel or visits to healthcare facilities other than the local dialysis center. Rapid flu test was positive for influenza A. Procalcitonin was elevated at 5.21 ng/mL with a normal white blood cell (WBC) count. Computed tomography (CT) chest demonstrated multifocal areas of consolidation and extensive mediastinal and hilar adenopathy concerning for pneumonia. He was admitted to the biocontainment unit of Nebraska Medicine for concerns of possible COVID-19 and was started on oseltamivir for influenza and vancomycin/cefepime for the probable bacterial cause of his pneumonia and diarrhea. GI pathogen panel and C. diff toxin assay were negative. On the second day of admission, initial nasopharyngeal swab came back positive for SARS-CoV-2 by RT-PCR. The patient received supportive care and resumed bedside hemodialysis in strict isolation, and eventually fully recovered from COVID-19.Conclusions: Our case demonstrated that co-infection of influenza and SARS-CoV-2 can occur in patients with no known direct exposure to COVID-19. The possibility of SARS-CoV-2 co-infection should not be overlooked even when other viruses including influenza can explain the clinical symptoms.

Current updates on COVID-19 - A review

2020 ◽  
Vol 10 (1) ◽  
pp. 1-8
Author(s):  
Ghotekar D S ◽  
Vishal N Kushare ◽  
Sagar V Ghotekar
Keyword(s):  
World Health Organization ◽  
Common Cold ◽  
Respiratory Diseases ◽  
Gastrointestinal Diseases ◽  
Hubei Province ◽  
World Health ◽  
The World ◽  
The Common ◽  
Novel Coronavirus ◽  
Health Organization

Coronaviruses are a family of viruses that cause illness such as respiratory diseases or gastrointestinal diseases. Respiratory diseases can range from the common cold to more severe diseases. A novel coronavirus outbreak was first documented in Wuhan, Hubei Province, China in December 2019. The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) a pandemic. A global coordinated effort is needed to stop the further spread of the virus. A novel coronavirus (nCoV) is a new strain that has not been identified in humans previously. Once scientists determine exactly what coronavirus it is, they give it a name (as in the case of COVID-19, the virus causing it is SARS-CoV-2).

An approach to the understanding of the clinical-etiopathological aspect of COVID-19 (SARS-CoV-2)

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 862-869
Author(s):  
Meena Kumari ◽  
Monika Agrawal ◽  
Rakesh Kumar Singh ◽  
Parameswarappa S Byadgi
Keyword(s):  
World Health ◽  
Apical Surface ◽  
Therapy Assessment ◽  
Differentiated Cells ◽  
The World ◽  
Polarized Epithelia ◽  
Well Differentiated ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Epidemiological Characteristics

Currently, the world is facing a health and socioeconomic crisis caused by the novel coronavirus disease COVID-19. On 11 March 2020, the World Health Organization (WHO) has declared this disease as a pandemic. The condition (COVID-19) is an infectious disorder triggered by a newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2. Most of the COVID-19 infected patients will experience mild to moderate respiratory symptoms and recover without any unique therapy. Assessment of the clinical and epidemiological characteristics of SARS-CoV-2 cases suggests the infected patients will not be contagious until the onset of severe symptoms and affects the other organs. Well-differentiated cells of apical airway epithelia communicating with ACE2 were promptly infected to SARS-CoV-2 virus. But the expression of ACE 2 in poorly differentiated epithelia facilitated SARS spike (S) protein-pseudo typed virus entry and it is replicated in polarized epithelia and especially exited via the apical surface. Limiting the transmission of COVID-19 infection & its prevention can be regarded as a hierarchy of controls. In this article, we briefly discuss the most recent advances in respect to aetiology, pathogenesis and clinical progression of the disease COVID-19.

Treatment Options in COVID-19: The Role of Bioavailable Antiviral Ribonucleoside Analog on NHC in vitro

2020 ◽  
Author(s):  
Lara Bittmann
Keyword(s):  
World Health Organization ◽  
Clinical Picture ◽  
Treatment Options ◽  
World Health ◽  
Wuhan City ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic.

Novel Coronavirus 2019 Outbreak: A Global Epidemic

2020 ◽  
Vol 17 (12) ◽  
pp. 1458-1464
Author(s):  
Sweta Kamboj ◽  
Rohit Kamboj ◽  
Shikha Kamboj ◽  
Kumar Guarve ◽  
Rohit Dutt
Keyword(s):  
World Health ◽  
Upper Respiratory Tract ◽  
Global Epidemic ◽  
The Public ◽  
The Government ◽  
Tract Disease ◽  
The 1960S ◽  
Novel Coronavirus ◽  
Health Organization ◽  
The Impact

Background: In the 1960s, the human coronavirus was designated, which is responsible for the upper respiratory tract disease in children. Back in 2003, mainly 5 new coronaviruses were recognized. This study directly pursues to govern knowledge, attitude and practice of viral and droplet infection isolation safeguard among the researchers during the outbreak of the COVID-19. Introduction: Coronavirus is a proteinaceous and infectious pathogen. It is an etiological agent of severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). Coronavirus, appeared in China from the seafood and poultry market last year, which has spread in various countries, and has caused several deaths. Methods: The literature data has been taken from different search platforms like PubMed, Science Direct, Embase, Web of Science, who.int portal and complied. Results: Corona virology study will be more advanced and outstanding in recent years. COVID-19 epidemic is a threatening reminder not solely for one country but all over the universe. Conclusion: In this review article, we encapsulated the pathogenesis, geographical spread of coronavirus worldwide, also discussed the perspective of diagnosis, effective treatment, and primary recommendations by the World Health Organization, and guidelines of the government to slow down the impact of the virus are also optimistic, efficacious and obliging for the public health. However, it will take a prolonged time in the future to overcome this epidemic.

An Efficient Approach for Detection and Verification of Infected Cases of Covid-19 Virus through Block Chain: A Survey

2020 ◽  
Vol 10 ◽  
Author(s):  
Kanika Gupta ◽  
Aatif Jamshed
Keyword(s):  
Data Storage ◽  
Operations Management ◽  
World Health ◽  
Chain Model ◽  
Human Beings ◽  
Healthcare Applications ◽  
Food Market ◽  
Block Chain ◽  
Novel Coronavirus ◽  
Health Organization

: Some unknown cases of pneumonia were communicated to World Health Organization (WHO) on 31 December,2019 in China’s Wuhan state. The higher authorities of China informed novel coronavirus as the root cause and labelled as “nCov-2019”. This virus is lying into the virus’s family which propagates the diseases like cold flu, lungs infection and more serious diseases. It is not detected earlier in human beings as it is considered to be a new patch on life. Many countries have increased their surveillance forces around the globe to detect any new novel coronavirus cases. An efficient and safe network for secure data storage i.e. Block chain is used in several applications such as food market, healthcare applications, finance, operations management, Internet of Things (IoT). In this paper, with the use of this emerging technology, are able to track useful information and accelerate the treatment process of patients. It also preserves the person’s identity. Correct implementation of block chain model has the chances to restrict the coronavirus transmissions and its related mortality rate where there are inadequate facilities of testing. Other infectious diseases will also be curbed by this model. The advantages of this model can reach to various stakeholders who are involved in the healthcare field which helps us to restrict the transmission of various diseases.

Critical Insight into the Attributes of Emerging Novel Coronavirus (COVID-19) in India and Across the World

Coronaviruses ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. 49-56
Author(s):  
Gaurav M. Doshi ◽  
Hemen S. Ved ◽  
Ami P. Thakkar
Keyword(s):  
Review Article ◽  
World Health ◽  
Effective Vaccine ◽  
Human Contact ◽  
The World ◽  
Critical Insight ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Insight Into ◽  
Old Drugs

The World Health Organization (WHO) has recently announced the spread of novel coronavirus (nCoV) globally and has declared it a pandemic. The probable source of transmission of the virus, which is from animal to human and human to human contact, has been established. As per the statistics reported by the WHO on 11th April 2020, data has shown that more than sixteen lakh confirmed cases have been identified globally. The reported cases related to nCoV in India have been rising substantially. The review article discusses the characteristics of nCoV in detail with the probability of potentially effective old drugs that may inhibit the virus. The research may further emphasize and draw the attention of the world towards the development of an effective vaccine as well as alternative therapies. Moreover, the article will help to bridge the gap between the new researchers since it’s the current thrust area of research.

The Pandemic of Novel Coronavirus Disease 2019 (COVID-19): Need for an Immediate Action (Preprint)

2020 ◽  
Author(s):  
Mujib Ullah
Keyword(s):  
World Health Organization ◽  
Large Family ◽  
Current Treatment ◽  
World Health ◽  
New Disease ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

UNSTRUCTURED Coronaviruses belong to a large family of viruses. Coronavirus also called COVID-19 is a new disease that has not been previously identified in humans. The World Health Organization has announced that COVID-19 is a pandemic. Currently there is no specific vaccine or treatment for COVID-19. Current treatment for COVID-19 is only supportive (treating the symptoms). There are no antiviral or vaccine options at this time. Therefore, it is time to bring collective efforts to treat or prevent a rapidly evolving pandemic of COVID-19.

Possible role of Unani Pharmacology in COVID-19 – a narrative review

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Md Anzar Alam ◽  
Mohd Abdul Gani ◽  
G. Shama ◽  
Ghulamuddin Sofi ◽  
Mohd Aleemuddin Quamri
Keyword(s):  
Clinical Manifestations ◽  
Public Health Problem ◽  
World Health ◽  
Santalum Album ◽  
Boswellia Serrata ◽  
Unani Medicine ◽  
Significant Public Health Problem ◽  
Significant Public Health ◽  
Novel Coronavirus ◽  
Health Organization

AbstractAccording to the World Health Organization (WHO), viral diseases continue to rise, and pose a significant public health problem. Novel coronavirus disease (COVID-19) is an infectious disease caused by SARS-CoV-2. The pathogenesis and clinical manifestations of COVID-19 is close to Amraz-e-Wabai (epidemic diseases) which was described by Hippocrates, Galen, Aristotle, Razes, Haly Abbas, Avicenna, Jurjani etc. Presently, there is no specific or challenging treatment available for COVID-19. Renowned Unani Scholars recommended during epidemic situation to stay at home, and fumigate the shelters with aromatics herbs like Ood kham (Aquilaria agallocha Roxb.), Kundur (Boswellia serrata Roxb), Kafoor (Cinnamomum camphora L.), Sandal (Santalum album L), Hing (Ferula foetida L.) etc. Use of specific Unani formulations are claimed effective for the management of such epidemic or pandemic situation like antidotes (Tiryaqe Wabai, Tiryaqe Arba, Tiryaqe Azam, Gile Armani), Herbal Decoction (Joshandah), along with Sharbate Khaksi, Habbe Bukhar, Sharbate Zanjabeel, Khamira Marwareed, Jawarish Jalinus, and Sirka (vinegar). Such drugs are claimed for use as antioxidant, immunomodulatory, cardiotonic, and general tonic actions. The study enumerates the literature regarding management of epidemics in Unani medicine and attempts to look the same in the perspective of COVID-19 prevention and management.

scholarly journals Potential of CRISPR/Cas13 System in Treatment and Diagnosis of COVID-19

2021 ◽  
Author(s):  
Amir Khodavirdipour ◽  
Motahareh Piri ◽  
Sarvin Jabbari ◽  
Mohammad Khalaj-kondori
Keyword(s):  
Diagnostic Tool ◽  
Human Kidney ◽  
World Health ◽  
Rapid Review ◽  
The Novel ◽  
Rapid Action ◽  
Antiparasitic Drug ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Treatment And Diagnosis

AbstractThe novel coronavirus disease 2019 (COVID-19) belongs to coronaviridae families, like sarbecovirus (SARS), and causes pyrexia, pertussis, and acute respiratory distress syndrome (ARDS) in major. Started from Wuhan, China now forced the World Health Organization (WHO) to call it a pandemic. These dreadful figures elevate the need for rapid action for a rapid diagnostic tool, an efficacious therapy, or vaccine for such widespread disease. Here we reviewed all the latest research and trials including conventional antiviral medicines that have a narrow and finite effect on COVID-19. Recently, some advances have been made by a nucleotide/nucleoside analogues (NUC) inhibitor (remdesivir), ivermectin (antiparasitic drug), and convalescent plasma, the later one has more recently been approved by the Food and Drug Administration (FDA). In addition, a clinical-grade soluble human angiotensin-converting enzyme (ACE2), named hrsACE2, was able to inhibit the infection of human blood vessel organoids, as well as the human kidney organoids, by the virus. As of now, innovative therapeutics based on the CRISPR/Cas13d might overcome the challenge of COVID-19 either as a treatment option or precise and rapid diagnostic tool due to its rapid and precise nature. In this updated comprehensive rapid review, we try to cover all recent findings in terms of genomics, diagnosis, prevention, and treatment.

Sign in / Sign up

Export Citation Format

Share Document